|
GLO1 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 6.15430040262765E-10 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
3.14329995365625E-09 |
| Normal-vs-Stage2 |
1.423660E-02 |
| Normal-vs-Stage3 |
2.67150002120076E-09 |
| Normal-vs-Stage4 |
1.51910000134592E-08 |
| Stage1-vs-Stage2 |
8.371800E-02 |
| Stage1-vs-Stage3 |
3.401200E-01 |
| Stage1-vs-Stage4 |
1.928040E-01 |
| Stage2-vs-Stage3 |
2.871900E-02 |
| Stage2-vs-Stage4 |
1.903910E-02 |
| Stage3-vs-Stage4 |
5.875800E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
6.54960530255266E-11 |
| Normal-vs-AfricanAmerican |
7.768100E-02 |
| Normal-vs-Asian |
1.78310999999765E-05 |
| Caucasian-vs-AfricanAmerican |
4.549600E-02 |
| Caucasian-vs-Asian |
5.706400E-01 |
| AfricanAmerican-vs-Asian |
1.747950E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.18730000275846E-08 |
| Normal-vs-Female |
1.93019999983335E-09 |
| Male-vs-Female |
5.924600E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
9.77049999795199E-08 |
| Normal-vs-Age(41-60Yrs) |
3.72219999267287E-09 |
| Normal-vs-Age(61-80Yrs) |
3.81489999590201E-08 |
| Normal-vs-Age(81-100Yrs) |
6.918900E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
4.666000E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
5.662600E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
8.145000E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
8.998600E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
9.982400E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
9.627600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
6.907400E-01 |
| Classical-VS-Follicular |
1.491990E-01 |
| Classical-VS-Other |
7.763000E-01 |
| Classical-VS-Normal |
2.12609999605817E-08 |
| Tall-VS-Follicular |
1.831170E-01 |
| Tall-VS-Other |
8.436200E-01 |
| Tall-VS-Normal |
2.0408999999999E-05 |
| Follicular-VS-Other |
4.471600E-01 |
| Follicular-VS-Normal |
1.097560E-03 |
| Other-VS-Normal |
1.113050E-01 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
5.17020000145862E-08 |
| Normal-vs-N1 |
1.28949999567141E-08 |
| N0-vs-N1 |
1.157800E-01 |
|
|
